If Your Compounding Provider Shuts Down: Transition Guide

This Is Happening More Often Than You Think

The GLP-1 compounding landscape in 2026 looks nothing like it did even a year ago. The FDA declared the semaglutide shortage over in February 2025, which triggered an enforcement cascade that's still accelerating. In February 2026, the FDA publicly announced its intent to restrict GLP-1 active pharmaceutical ingredients used in non-approved compounded drugs. The same week, Hims & Hers launched — and within 48 hours pulled — a compounded oral semaglutide product after intense regulatory pressure.

Since then, the FDA has sent warning letters to dozens of telehealth companies and compounding pharmacies. Some have voluntarily shut down GLP-1 programs. Others have been forced to. And for the patients relying on those providers, the experience is jarring: one day you're getting your medication delivered, the next day you're staring at an email telling you your provider is "no longer offering this service."

This guide is for those people. Not theoretical — practical. What to do right now, step by step.

Step 1: Secure Your Medical Records (Do This Today)

The single most important thing you can do when you learn your provider is shutting down is request your records immediately. Don't wait until the announced closure date — by then, the staff may already be gone and the systems offline.

What to Request

You need four documents to make a seamless transition to a new provider:

• Current prescription details: Drug name, exact dose, frequency, and when you last filled
• Dose titration history: What doses you've been on and when you moved up — this tells your next provider where you are in your treatment
• Lab work and assessments: Any BMI measurements, metabolic panels, or A1C results from your initial consultation
• Treatment notes: Any side effects documented, dose adjustments made, or clinical decisions recorded

Most telehealth platforms store this in a patient portal. Download everything as PDF before your access gets cut. If there's no portal, send an email requesting your records — under HIPAA, they're legally required to provide them within 30 days, but explain the urgency and most will expedite.

Step 2: Understand What's Actually In Your Medication

This matters more than most people realize. Not all compounded semaglutide is the same, and knowing exactly what you've been taking determines your transition path.

Semaglutide base is the same active ingredient in FDA-approved Ozempic and Wegovy. If your compounded medication uses semaglutide base, transitioning to brand-name is straightforward — the dose equivalence is essentially 1:1.

Semaglutide sodium (or other salt forms) are not the same molecule the FDA approved. The FDA has explicitly warned that these salt forms are "unapproved new drugs" with unknown bioequivalence. If you've been on a salt form, your transition may require your new provider to adjust dosing more carefully.

Check your vial label or prescription records. If it says "semaglutide sodium" or any variant other than plain "semaglutide," mention this to your new provider — it affects how they titrate you.

Step 3: Choose Your Next Path

You have three realistic options. Each has trade-offs, and the right choice depends on your budget, insurance status, and how long you've been on treatment.

Option A: Switch to Another Compounded Provider

As of March 2026, compounded GLP-1 medications still exist — but the landscape is narrower and more legally fraught. The providers still operating tend to fall into two categories: 503B outsourcing facilities that are working within increasingly tight FDA guidelines, and 503A pharmacies compounding on a patient-specific basis with valid prescriptions.

What to look for in a replacement compounded provider:

• Uses a 503B-registered outsourcing facility (not just a local pharmacy with a compounding license)
• Can document their API (active pharmaceutical ingredient) sourcing from FDA-registered suppliers
• Performs third-party batch testing
• Has been in operation for more than 12 months (newer entrants carry more regulatory risk)
• Transparent about whether they're using semaglutide base vs. salt forms

Reality check: Compounded GLP-1 availability could tighten further at any time. If you choose this path, have a brand-name backup plan ready.

Option B: Transition to Brand-Name (Self-Pay)

This was prohibitively expensive a year ago. It's not anymore. The self-pay landscape has changed dramatically:

Brand-Name Option	Monthly Cost (Self-Pay)	Where to Buy
Wegovy Injectable	$349/month (all doses)	NovoCare Pharmacy
Wegovy Pill (25mg oral)	$149–$199/month	NovoCare Pharmacy
Zepbound Injectable	$299–$449/month	LillyDirect
Ozempic (off-label)	$349/month	NovoCare Pharmacy

The Wegovy pill at $149/month is now cheaper than many compounded options. That's a sentence no one expected to write in 2026, but here we are.

Option C: Get Insurance to Cover It

This takes longer but saves the most money long-term. If you have commercial insurance, here's the play:

• Check your formulary for Wegovy or Zepbound coverage (many plans added coverage in 2025-2026)
• If your plan requires a BMI-based qualification, get it documented by your PCP
• Use the manufacturer savings cards — with insurance coverage, both Wegovy and Zepbound can drop to $25/month
• If initially denied, file a prior authorization with your doctor's help — approval rates are much higher than most people realize

Medicare patients: Starting July 2026, the Medicare GLP-1 Bridge program will cover Wegovy and Zepbound at $50/month for qualifying beneficiaries. If your compounding provider is shutting down and you're on Medicare, this is your landing zone.

Step 4: Manage the Transition Gap

The most dangerous part of switching providers isn't the switch itself — it's the gap between your last dose and your first dose from the new provider. Here's what to expect and how to minimize it.

How Long Can You Go Without a Dose?

GLP-1 medications have a half-life of about 7 days for semaglutide and 5 days for tirzepatide. That means the drug stays active in your system for roughly 5-6 weeks after your last injection, though at progressively lower levels. You won't "crash" after missing one dose. But you will start noticing increased appetite within 2-3 weeks.

What to Do During the Gap

• If you have unused medication: Continue your current dosing schedule. Do not increase your dose to "stockpile" the effects — that's how dosing errors and side effects happen.
• If you're completely out: Focus on protein intake (≥100g/day), keep your meal schedule consistent, and avoid the "what's the point" mindset. The physiological changes GLP-1 medications created — improved insulin sensitivity, reduced inflammation — don't disappear overnight.
• Get your new provider set up now: Most telehealth platforms can get you a prescription within 24-72 hours of your consultation. Don't wait until your last vial is empty to start the process.

Step 5: Dose Matching at Your New Provider

When you transition, your new provider needs to know exactly where you are in your titration. Here's the standard dose mapping:

If You Were On (Compounded)	Brand-Name Equivalent	Notes
Semaglutide 0.25mg/week	Wegovy 0.25mg or Ozempic 0.25mg	Starting dose — direct match
Semaglutide 0.5mg/week	Wegovy 0.5mg or Ozempic 0.5mg	Direct match
Semaglutide 1.0mg/week	Wegovy 1.0mg or Ozempic 1.0mg	Direct match
Semaglutide 1.7mg/week	Wegovy 1.7mg	No Ozempic equivalent at this dose
Semaglutide 2.0mg/week	Ozempic 2.0mg	Ozempic only; Wegovy jumps to 2.4mg
Semaglutide 2.4mg/week	Wegovy 2.4mg	Maximum maintenance dose
Tirzepatide 2.5–15mg/week	Zepbound (same doses)	Direct match across all dose levels

Important: If you were on a compounded dose that doesn't match standard tiers (e.g., 1.25mg semaglutide — a common compounding dose that doesn't exist in brand-name), your provider will round to the nearest available dose, usually the lower one, and titrate from there.

What NOT to Do

In a scramble to maintain treatment, people make mistakes. Avoid these:

• Don't buy from unverified online sellers. The FDA has identified fraudulent compounded semaglutide and tirzepatide products with fake pharmacy labels. Some of these products don't contain what they claim, and some have caused hospitalizations from dosing errors.
• Don't use "research-grade" peptides. Products labeled "not for human consumption" or "for research purposes only" are exactly what they say. The FDA has sent warning letters to companies selling these directly to consumers.
• Don't double up on doses to "catch up" if you miss a week. Resume at your normal dose on your normal schedule.
• Don't panic. Missing a few weeks of medication is not ideal, but it's not catastrophic. Your body doesn't reset to zero.

The Bigger Picture: Why This Keeps Happening

The compounding provider shutdowns in 2026 aren't random — they're the predictable result of a regulatory cycle that started when the FDA declared semaglutide shortages resolved. Here's the pattern:

1. During the shortage (2022–early 2025), compounding was legally permitted under FDA's enforcement discretion
2. Shortage ends → enforcement discretion expires → FDA begins sending warning letters
3. February 2026: FDA publicly announces intent to restrict GLP-1 APIs for non-approved compounded products
4. March 2026: FDA sends enforcement actions to 30+ telehealth companies for misleading advertising
5. Compounders either adapt (shifting to patient-specific, medically necessary compounding) or shut down

This trend will continue. If you're on a compounded GLP-1, having a transition plan isn't pessimism — it's preparation. Know your dose, know your records, and know your brand-name options. The providers who are still standing in mid-2026 are likely the ones doing it right, but even they operate in a rapidly shifting regulatory environment.

The good news: the brand-name self-pay market has never been more accessible. The Wegovy pill at $149/month, Zepbound vials at $299/month, and Medicare coverage arriving in July 2026 mean that the transition from compounded to brand-name is no longer the financial cliff it used to be.